Scopinpharm plans to invest about 4 billion rubles in a platform for deep localization of the production of six innovative oncological and hematological drugs from Novartis, Inga Nizharadze, the Director General of Scopinpharm said. The Swiss company, in turn, will provide technology transfer.
Novartis Pharma, a Swiss company, is ready to invest 3.5 billion rubles in the creation of anti-cancer medicines production in the Ryazan Region. This was announced by Nikolay Lyubimov, Governor of the Ryazan Region, on Wednesday in his message about the regional priorities.
Novartis, an international pharmaceutical corporation, has invested $150 million in a medicines production plant in St. Petersburg. This was announced to TASS by the President of Novartis group of companies in Russia Vadim Vlasov at the launch of the first facility for the production of the finished full cycle medicines.
Novartis, pharmaceutical company, plans to localize the production of about 40 drugs, classified as socially significant, in the territory of the special economic zone in St. Petersburg. This decision was announced on Monday by the press service of Sergey Movchan, vice-governor of the city, who took part in the ceremony on opening a production line of the company.
Pharmaceutical and medical companies Novartis, Geropharm and Orion Medic intend to arrange commercial production of some of their medicines and equipment in Saint Petersburg by late 2017. Today, the President of Saint Petersburg Committee for Industrial Policy and Innovation reported it.
Novartis and Orion Medic's plants are in the Novoorlovskaya SEZ. Novartis plans launching commercial production of its proprietary drugs in November with Orion Medic to follow suit — in December.
On 19 June, Novartis Neva opened a factory in the Novoorlovskaya Special Economic Zone. The total amount of investment in the project is 4.5 billion roubles (around $83 million), with 350 jobs to be created.
Swiss company Novartis started construction of the pharmaceutical manufacturing facility in line with GMP Standards back in 2011. The facility will produce 1.5 billion units of solid dosage forms per year. The project includes the development and production of more than 40 brand name medicines, including high-quality generic Sandoz drugs and original Novartis Pharma products (both companies are part of the Novartis Group). The medicines are intended for use in the following areas: cardiology, neurology, organ transplantation, oncology, gastroenterology and diabetes.
The project has been implemented as part of Novartis’ $500-million strategic investment programme in Russia, which it launched in 2010. The programme involves the organisation of local production and cooperation in research and development.
At present, three production lines have been installed at the new facility. After the equipment has been set up, test release of the medicines will begin, followed by the drug registration procedure. Commercial launch is planned for 2017. Having its own production facilities in Russia will allow Novartis to reduce the price of its products by at least 10%.
Novartis came into being in 1996 following the merger of Ciba-Geigy and Sandoz, two companies with rich and varied corporate histories. It is now one of the largest pharmaceutical companies in the world, employing 136,000 people in 150 countries. All of the company’s sub-divisions are represented in Russia: Novartis Pharma, Sandoz, Alcon, Novartis OTC, Novartis Vaccines and Diagnostics and Novartis Animal Health.
Switzerland-based pharmaceutical company Novartis AG is set to open a new production facility in St Petersburg in June 2015.
The new plant, which is located in the Special Economic Zone (SEZ) in St Petersburg, required an investment of USD 140 million and is set to manufacture up to approximately 1.7 billion tablets per year.
Company's website: www.novartis.com/
T: +41 613241111
Public company (NYSE: NVS)
Contact: Mr Joseph Jimenez, Chief Executive Officer
Novartis is one of the world's largest drug firms. Its Sandoz generics subsidiary produces finished dosage products as well as active pharmaceutical ingredients for other generic drug companies to manufacture.